Third-generation EGFR and ALK inhibitors: mechanisms of resistance and management
Third-generation EGFR and ALK inhibitors: mechanisms of resistance and management
About this item
Full title
Author / Creator
Publisher
London: Nature Publishing Group UK
Journal title
Language
English
Formats
Publication information
Publisher
London: Nature Publishing Group UK
Subjects
More information
Scope and Contents
Contents
The discoveries of
EGFR
mutations and
ALK
rearrangements as actionable oncogenic drivers in non-small-cell lung cancer (NSCLC) has propelled a biomarker-directed treatment paradigm for patients with advanced-stage disease. Numerous EGFR and ALK tyrosine kinase inhibitors (TKIs) with demonstrated efficacy in patients with
EGFR
-mut...
Alternative Titles
Full title
Third-generation EGFR and ALK inhibitors: mechanisms of resistance and management
Authors, Artists and Contributors
Author / Creator
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_9621058
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_9621058
Other Identifiers
ISSN
1759-4774,1759-4782
E-ISSN
1759-4782
DOI
10.1038/s41571-022-00639-9
